NCT05582096View on ClinicalTrials.gov

A Study of LY3457263 in Obese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

38

Participants

Timeline

Start Date

November 11, 2022

Primary Completion Date

June 8, 2023

Study Completion Date

June 8, 2023

Conditions

OverweightObesity

Interventions

DRUG

LY3457263

Administered SC.

DRUG

Tirzepatide

Administered SC.

DRUG

Placebo

Administered SC.

Trial Locations (1)

32117

LabCorp CRU, Inc., Daytona Beach

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY